Kerollos Nashat Wanis1, Suzana Buac1, Michael Linecker2, Victoria Ardiles3, Mauro Enrique Tun-Abraham1,4, Ricardo Robles-Campos5, Massimo Malago6, Eduardo de Santibañes3, Pierre-Alain Clavien2, Roberto Hernandez-Alejandro7. 1. Department of Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. 2. Swiss HPB and Transplant Center, University Hospital Zurich, Zurich, Switzerland. 3. Department of Surgery, Division of HPB Surgery, Liver Transplant Unit, Italian Hospital Buenos Aires, Buenos Aires, Argentina. 4. Multi-Organ Transplant Program, London Health Sciences Center, London, ON, Canada. 5. Department of General Surgery, Liver Transplant Unit, Virgen De La Arrixaca University Hospital, Murcia, Spain. 6. Department of HPB and Liver Transplant Surgery, Royal Free Hospital, University College London, London, UK. 7. Division of Hepatobiliary Surgery and Transplantation, Department of Surgery, University of Rochester, 601 Elmwood Avenue, Rochester, NY, 14642, USA. Roberto_Hernandez@urmc.rochester.edu.
Abstract
BACKGROUND: Liver resection combined with colorectal surgery (CRS) is the only curative option in many patients presenting with synchronous colorectal cancer and liver metastases (CRLM). Simultaneous resection has been shown to offer benefits in patients with low hepatic tumor load; however, in the setting of in situ colorectal tumor with extensive CRLM and a small predicted future liver remnant (FLR), the use of simultaneous ALPPS and CRS is controversial, lacking outcome data. METHODS: Thirty-one cases of simultaneous ALPPS and CRS prospectively entered into the International ALPPS Registry were examined. Univariate analysis was used to identify factors associated with 90-day mortality after stage-2. RESULTS: Thirty patients (97%) completed both stages. CRS was performed during stage-1 in 22 patients (73%). Seven patients (23%) had severe complications (Clavien-Dindo ≥ IIIb) following stage-2 ALPPS. The 90-day mortality rate was 15%. Patients who had a severe complication after stage-1 were significantly more likely to have 90-day mortality following stage-2 (p = 0.002). MELD score > 10 on postoperative day-5 after stage-1 was also significantly associated with 90-day mortality (p = 0.011). Disease-free survival and overall survival were 36% and 76% at 1 year, respectively. CONCLUSIONS: In light of the high mortality and poor long-term survival identified in this series, the adoption of ALPPS with CRS cannot be recommended without further data. Patients who suffer severe complications or have an elevated MELD score after stage-1 are at higher risk of mortality following stage-2.
BACKGROUND: Liver resection combined with colorectal surgery (CRS) is the only curative option in many patients presenting with synchronous colorectal cancer and liver metastases (CRLM). Simultaneous resection has been shown to offer benefits in patients with low hepatic tumor load; however, in the setting of in situ colorectal tumor with extensive CRLM and a small predicted future liver remnant (FLR), the use of simultaneous ALPPS and CRS is controversial, lacking outcome data. METHODS: Thirty-one cases of simultaneous ALPPS and CRS prospectively entered into the International ALPPS Registry were examined. Univariate analysis was used to identify factors associated with 90-day mortality after stage-2. RESULTS: Thirty patients (97%) completed both stages. CRS was performed during stage-1 in 22 patients (73%). Seven patients (23%) had severe complications (Clavien-Dindo ≥ IIIb) following stage-2 ALPPS. The 90-day mortality rate was 15%. Patients who had a severe complication after stage-1 were significantly more likely to have 90-day mortality following stage-2 (p = 0.002). MELD score > 10 on postoperative day-5 after stage-1 was also significantly associated with 90-day mortality (p = 0.011). Disease-free survival and overall survival were 36% and 76% at 1 year, respectively. CONCLUSIONS: In light of the high mortality and poor long-term survival identified in this series, the adoption of ALPPS with CRS cannot be recommended without further data. Patients who suffer severe complications or have an elevated MELD score after stage-1 are at higher risk of mortality following stage-2.
Authors: Skye C Mayo; Carlo Pulitano; Hugo Marques; Jorge Lamelas; Christopher L Wolfgang; Wassila de Saussure; Michael A Choti; Isabelle Gindrat; Luca Aldrighetti; Eduardo Barrosso; Gilles Mentha; Timothy M Pawlik Journal: J Am Coll Surg Date: 2013-02-21 Impact factor: 6.113
Authors: Erik Schadde; Victoria Ardiles; Ricardo Robles-Campos; Massimo Malago; Marcel Machado; Roberto Hernandez-Alejandro; Olivier Soubrane; Andreas A Schnitzbauer; Dimitri Raptis; Christoph Tschuor; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz Journal: Surgery Date: 2011-01-14 Impact factor: 3.982
Authors: Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: M Karoui; L Vigano; P Goyer; A Ferrero; A Luciani; M Aglietta; C Delbaldo; S Cirillo; L Capussotti; D Cherqui Journal: Br J Surg Date: 2010-09 Impact factor: 6.939
Authors: René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth Journal: Ann Surg Date: 2004-12 Impact factor: 12.969
Authors: Fernando A Alvarez; Victoria Ardiles; Martin de Santibañes; Juan Pekolj; Eduardo de Santibañes Journal: Ann Surg Date: 2015-04 Impact factor: 12.969
Authors: Mohammad Golriz; Anastasia Lemekhova; Elias Khajeh; Omid Ghamarnejad; Mohammed Al-Saeedi; Oliver Strobel; Thilo Hackert; Beat Müller-Stich; Martin Schneider; Christoph Berchtold; Parham Tinoush; Philipp Mayer; De-Hua Chang; Karl Heinz Weiss; Katrin Hoffmann; Arianeb Mehrabi Journal: BMJ Open Date: 2019-10-11 Impact factor: 2.692